{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:00:10Z","timestamp":1793505610694,"version":"4.5.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1245\/s10434-021-10193-w","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T14:02:53Z","timestamp":1623938573000},"page":"9098-9113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["HIPEC Methodology and Regimens: The Need for an Expert Consensus"],"prefix":"10.1245","volume":"28","author":[{"given":"Aditi","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"de Hingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Van Der Speeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Deraco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoual","family":"Bakrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kusamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Glehen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"10193_CR1","first-page":"256","volume":"40","author":"JD Spratt","year":"1980","unstructured":"Spratt JD, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256\u201360.","journal-title":"Cancer Res."},{"issue":"2 Pt 2","key":"10193_CR2","first-page":"358","volume":"10","author":"S Koga","year":"1983","unstructured":"Koga S, Shimizu N, Maeta M, Hamazoe R, Izumi A. Application of heat combined with antineoplastic agent administration in the treatment of cancer (with special reference to malignancy of the digestive system). Gan To Kagaku Ryoho. 1983;10(2 Pt 2):358\u201365.","journal-title":"Gan To Kagaku Ryoho."},{"key":"10193_CR3","volume-title":"Treatment of Peritoneal Surface Malignancies","author":"P Trenta","year":"2015","unstructured":"Trenta P, Giovannoni S, Risi E, The CE role of systemic chemotherapy. In: Di Giorgio A, Pinto E, editors. Treatment of Peritoneal Surface Malignancies. State of the Art and Perspectives. Italia: Springer-Verlag; 2015."},{"key":"10193_CR4","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/978-3-642-81488-4_31","volume":"74","author":"JL Speyer","year":"1980","unstructured":"Speyer JL, Myers CE. The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies. Recent Results Cancer Res. 1980;74:264\u20139.","journal-title":"Recent Results Cancer Res."},{"key":"10193_CR5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1055-3207(03)00034-6","volume":"12","author":"MH Katz","year":"2003","unstructured":"Katz MH, Barone RM. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am. 2003;12:673\u201388.","journal-title":"Surg Oncol Clin N Am."},{"key":"10193_CR6","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, De Vita Jr. VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1\u201311.","journal-title":"Cancer Treat Rep."},{"key":"10193_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1515\/pp-2016-0015","volume":"1","author":"W Solass","year":"2016","unstructured":"Solass W, Horvath P, Struller F, K\u00f6nigsrainer I, Beckert S, K\u00f6nigsrainer A, et al. Functional vascular anatomy of the peritoneum in health and disease. Pleura Peritoneum. 2016;1:145\u201358. https:\/\/doi.org\/10.1515\/pp-2016-0015.","journal-title":"Pleura Peritoneum"},{"key":"10193_CR8","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/jso.25899","volume":"121","author":"MK Stein","year":"2020","unstructured":"Stein MK, Williard FW, Xiu J, Tsao MW, Martin MG, Deschner BW, et al. Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. J Surg Oncol. 2020;121:1320\u20138. https:\/\/doi.org\/10.1002\/jso.25899.","journal-title":"J Surg Oncol."},{"key":"10193_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/his.13324","volume":"71","author":"NJ Carr","year":"2017","unstructured":"Carr NJ, Bibeau F, Bradley RF, Dartigues P, Feakins RM, Geisinger KR, et al. The histopathological classification, diagnosis, and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas, and pseudomyxoma peritonei. Histopathology. 2017;71:847\u201358. https:\/\/doi.org\/10.1111\/his.13324.","journal-title":"Histopathology."},{"key":"10193_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/IJWH.S30231","volume":"5","author":"Z Kemp","year":"2013","unstructured":"Kemp Z, Ledermann J. Update on first-line treatment of advanced ovarian carcinoma. Int J Womens Health. 2013;5:45\u201351. https:\/\/doi.org\/10.2147\/IJWH.S30231.","journal-title":"Int J Womens Health."},{"key":"10193_CR11","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","volume":"33","author":"S B\u00f6hm","year":"2015","unstructured":"B\u00f6hm S, Faruqi A, Said I, et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol. 2015;33:2457\u201363. https:\/\/doi.org\/10.1200\/JCO.2014.60.5212.","journal-title":"J Clin Oncol."},{"key":"10193_CR12","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1245\/s10434-007-9768-y","volume":"15","author":"DL Bartlett","year":"2008","unstructured":"Bartlett DL. HIPEC: the complexities of clinical trials. Ann Surg Oncol. 2008;15:1277\u20139. https:\/\/doi.org\/10.1245\/s10434-007-9768-y.","journal-title":"Ann Surg Oncol."},{"key":"10193_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.02.030","author":"RN Low","year":"2019","unstructured":"Low RN, Barone RM, Rousset P. Peritoneal MRI in patients undergoing cytoreductive surgery and HIPEC: history, clinical applications, and implementation. Eur J Surg Oncol. 2019. https:\/\/doi.org\/10.1016\/j.ejso.2019.02.030.","journal-title":"Eur J Surg Oncol."},{"key":"10193_CR14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/02656736.2017.1306119","volume":"33","author":"C Honor\u00e9","year":"2017","unstructured":"Honor\u00e9 C, Gelli M, Francoual J, Benhaim L, Elias D, Go\u00e9r\u00e9 D. Ninety percent of the adverse outcomes occur in 10 % of patients: can we identify the populations at high risk of developing peritoneal metastases after curative surgery for colorectal cancer? Int J Hyperthermia. 2017;33:505\u201310. https:\/\/doi.org\/10.1080\/02656736.2017.1306119.","journal-title":"Int J Hyperthermia."},{"key":"10193_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s13193-016-0502-8","volume":"7","author":"RA Seshadri","year":"2016","unstructured":"Seshadri RA, Glehen O. The role of hyperthermic intraperitoneal chemotherapy in gastric cancer. Ind J Surg Oncol. 2016;7:198\u2013207. https:\/\/doi.org\/10.1007\/s13193-016-0502-8.","journal-title":"Ind J Surg Oncol."},{"key":"10193_CR16","doi-asserted-by":"publisher","first-page":"20180102","DOI":"10.1515\/pp-2018-0102.PMID:30911652;PMCID:PMC6405010","volume":"3","author":"J Franko","year":"2018","unstructured":"Franko J. Therapeutic efficacy of systemic therapy for colorectal peritoneal carcinomatosis: surgeon\u2019s perspective. Pleura Peritoneum. 2018;3:20180102. https:\/\/doi.org\/10.1515\/pp-2018-0102.PMID:30911652;PMCID:PMC6405010.","journal-title":"Pleura Peritoneum."},{"key":"10193_CR17","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al. Analysis and Research in Cancers of the Digestive System (ARCAD) group. Lancet Oncol. 2016;17:1709\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(16)30500-9.","journal-title":"Lancet Oncol."},{"key":"10193_CR18","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09330-8","author":"A Bhatt","year":"2020","unstructured":"Bhatt A, Rousset P, Benzerdjeb N, et al. Clinical and radiologic predictors of a pathologic complete response to neoadjuvant chemotherapy (NACT) in patients undergoing cytoreductive surgery for colorectal peritoneal metastases: results of a prospective multi-center study. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-09330-8.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"10193_CR19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1080\/02656736.2017.1291999","volume":"33","author":"L Lemoine","year":"2017","unstructured":"Lemoine L, Sugarbaker P, van der Speeten K. Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. Int J Hyperthermia. 2017;33(5):582\u201392. https:\/\/doi.org\/10.1080\/02656736.2017.1291999.","journal-title":"Int J Hyperthermia."},{"key":"10193_CR20","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737\u201343. https:\/\/doi.org\/10.1200\/JCO.2003.04.187.","journal-title":"J Clin Oncol."},{"key":"10193_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63\u20138. https:\/\/doi.org\/10.1200\/JCO.2009.23.9285.","journal-title":"J Clin Oncol."},{"key":"10193_CR22","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/jso.23545","volume":"109","author":"CQ Huang","year":"2014","unstructured":"Huang CQ, Feng JP, Yang XJ, Li Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: a case\u2013control study from a Chinese center. J Surg Oncol. 2014;109:730\u20139. https:\/\/doi.org\/10.1002\/jso.23545.","journal-title":"J Surg Oncol."},{"key":"10193_CR23","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37:2028\u201340. https:\/\/doi.org\/10.1200\/JCO.18.01688.","journal-title":"J Clin Oncol."},{"key":"10193_CR24","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1708618.","journal-title":"N Engl J Med."},{"issue":"3","key":"10193_CR25","doi-asserted-by":"publisher","first-page":"e206363","DOI":"10.1001\/jamasurg.2020.6363","volume":"156","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, Barretta F, Yonemura Y, Sugarbaker PH, Moran BJ, Levine EA, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156(3):e206363.\u00a0https:\/\/doi.org\/10.1001\/jamasurg.2020.6363.","journal-title":"JAMA Surg."},{"key":"10193_CR26","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","volume":"30","author":"TC Chua","year":"2012","unstructured":"Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449\u201356.","journal-title":"J Clin Oncol."},{"key":"10193_CR27","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1245\/s10434-006-9182-x","volume":"14","author":"TD Yan","year":"2007","unstructured":"Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007;14:484\u201392.","journal-title":"Ann Surg Oncol."},{"key":"10193_CR28","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, Sugarbaker PH, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237\u201342.","journal-title":"J Clin Oncol."},{"key":"10193_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34\u201343. https:\/\/doi.org\/10.1056\/NEJMoa052985.","journal-title":"N Engl J Med."},{"key":"10193_CR30","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1200\/JCO.18.01568","volume":"37","author":"JL Walker","year":"2019","unstructured":"Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology\/Gynecologic Oncology Group study. J Clin Oncol. 2019;37:1380\u201390. https:\/\/doi.org\/10.1200\/JCO.18.01568 (Erratum. In: J Clin Oncol. 2019;37:2299).","journal-title":"J Clin Oncol."},{"key":"10193_CR31","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950\u20135.","journal-title":"N Engl J Med."},{"key":"10193_CR32","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001\u20137.","journal-title":"J Clin Oncol."},{"key":"10193_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejca.2015.09.017","volume":"53","author":"PH Cashin","year":"2016","unstructured":"Cashin PH, Mahteme H, Sp\u00e5ng N, Syk I, Fr\u00f6din JE, Torkzad M, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer. 2016;53:155\u201362. https:\/\/doi.org\/10.1016\/j.ejca.2015.09.017.","journal-title":"Eur J Cancer."},{"key":"10193_CR34","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1245\/s10434-013-3443-2","volume":"21","author":"E Canbay","year":"2014","unstructured":"Canbay E, Mizumoto A, Ichinose M, Ishibashi H, Sako S, Hirano M, et al. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol. 2014;21:1147\u201352.","journal-title":"Ann Surg Oncol."},{"key":"10193_CR35","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","volume":"20","author":"M Alyami","year":"2019","unstructured":"Alyami M, H\u00fcbner M, Grass F, Bakrin N, Villeneuve L, Laplace N, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20:e368\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(19)30318-3.","journal-title":"Lancet Oncol."},{"key":"10193_CR36","doi-asserted-by":"crossref","first-page":"F433","DOI":"10.1152\/ajprenal.00313.2004","volume":"288","author":"MF Flessner","year":"2005","unstructured":"Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol. 2005;288:F433\u201342.","journal-title":"Am J Physiol Renal Physiol."},{"key":"10193_CR37","first-page":"131","volume":"134","author":"MF Flessner","year":"2007","unstructured":"Flessner MF. Intraperitoneal drug therapy: physical and biological principles. Cancer Treat Res. 2007;134:131\u201352.","journal-title":"Cancer Treat Res."},{"key":"10193_CR38","first-page":"188","volume-title":"Atlas and principles of peritonectomy for peritoneal surface malignancy","author":"Y Yonemura","year":"2012","unstructured":"Yonemura Y. Trans-lymphatic metastasis. In: Yonemura Y, editor. Atlas and principles of peritonectomy for peritoneal surface malignancy. Kyoto: NPO to support peritoneal surface malignancy; 2012. p. 188\u2013206."},{"key":"10193_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4172\/2324-9110.1000130","volume":"3","author":"Y Yonemura","year":"2014","unstructured":"Yonemura Y, Canbay E, Endou Y, et al. Mechanisms of the formation of peritoneal surface malignancy on omental milky spots from low-grade appendiceal mucinous carcinoma. J Clin Exp Oncol. 2014;3:3. https:\/\/doi.org\/10.4172\/2324-9110.1000130.","journal-title":"J Clin Exp Oncol."},{"key":"10193_CR40","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00464-011-1964-y","volume":"26","author":"W Solass","year":"2012","unstructured":"Solass W, Herbette A, Schwarz T, Hetzel A, Sun JS, Dutreix M, Reymond MA. Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination capnoperitoneum: proof of concept. Surg Endosc. 2012;26:847\u201352. https:\/\/doi.org\/10.1007\/s00464-011-1964-y.","journal-title":"Surg Endosc."},{"key":"10193_CR41","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1245\/s10434-015-4954-9","volume":"23","author":"V Khosrawipour","year":"2016","unstructured":"Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Forster E, Zieren J, Giger-Pabst U. Exploring the spatial drug distribution pattern of pressurized Intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2016;23:1220\u20134.","journal-title":"Ann Surg Oncol."},{"key":"10193_CR42","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00432-016-2234-0","volume":"142","author":"V Khosrawipour","year":"2016","unstructured":"Khosrawipour V, Khosrawipour T, Kern AJ, Osma A, Kabakci B, Diaz-Carballo D, et al. Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. J Cancer Res Clin Oncol. 2016;142:2275\u201380. https:\/\/doi.org\/10.1007\/s00432-016-2234-0.","journal-title":"J Cancer Res Clin Oncol."},{"key":"10193_CR43","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00464-016-5174-5","volume":"31","author":"D G\u00f6hler","year":"2017","unstructured":"G\u00f6hler D, Khosrawipour V, Khosrawipour T, et al. Technical description of the microinjection pump (MIP\u00ae) and granulometric characterization of the aerosol applied for pressurized intraperitoneal aerosol chemotherapy (PIPAC). Surg Endosc. 2017;31:1778\u201384. https:\/\/doi.org\/10.1007\/s00464-016-5174-5.","journal-title":"Surg Endosc."},{"key":"10193_CR44","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejso.2019.06.028","volume":"47","author":"M Alyami","year":"2021","unstructured":"Alyami M, Mercier F, Siebert M, Bonnot PE, Laplace N, Villeneuve L, et al. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2021;47:128\u201333. https:\/\/doi.org\/10.1016\/j.ejso.2019.06.028.","journal-title":"Eur J Surg Oncol."},{"key":"10193_CR45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jso.21321","volume":"100","author":"M Valle","year":"2009","unstructured":"Valle M, Van der Speeten K, Garofalo A. Laparoscopic hyperthermic peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional analysis in 52 patients. J Surg Oncol. 2009;100:331\u20134.","journal-title":"J Surg Oncol."},{"key":"10193_CR46","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/BF02409050","volume":"3","author":"S Schneebaum","year":"1996","unstructured":"Schneebaum S, Arnold MW, Staubus A, Young DC, Dumond D, Martin EW Jr. Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Ann Surg Oncol. 1996;3:44\u201350.","journal-title":"Ann Surg Oncol."},{"key":"10193_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1515\/pp-2017-0012","volume":"22","author":"PH Sugarbaker","year":"2017","unstructured":"Sugarbaker PH. Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy: an overview. Pleura Peritoneum. 2017;22:85\u201393. https:\/\/doi.org\/10.1515\/pp-2017-0012.","journal-title":"Pleura Peritoneum."},{"issue":"Suppl 1","key":"10193_CR48","first-page":"3","volume":"10","author":"Y Yonemura","year":"2019","unstructured":"Yonemura Y, Sako S, Wakama S, Ishibashi H, Mizumoto A, Takao N, et al. History of peritoneal surface malignancy treatment in Japan. J Surg Oncol. 2019;10(Suppl 1):3\u201311.","journal-title":"J Surg Oncol."},{"key":"10193_CR49","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1055-3207(03)00029-2","volume":"12","author":"RP Sticca","year":"2003","unstructured":"Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12:689\u2013701.","journal-title":"Surg Oncol Clin N Am."},{"key":"10193_CR50","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/02656730701455318","volume":"23","author":"PH Sugarbaker","year":"2007","unstructured":"Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperth. 2007;23:431\u201342.","journal-title":"Int J Hyperth."},{"key":"10193_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30599-4","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4.","journal-title":"Lancet Oncol."},{"issue":"4","key":"10193_CR52","doi-asserted-by":"publisher","first-page":"20180131","DOI":"10.1515\/pp-2018-0131","volume":"3","author":"A Konisgrainer","year":"2018","unstructured":"Konisgrainer A, Rau B. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): don\u2019t throw the baby out with the bathwater. Pleura Peritoneum. 2018;3(4):20180131. https:\/\/doi.org\/10.1515\/pp-2018-0131.","journal-title":"Pleura Peritoneum."},{"key":"10193_CR53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1515\/pp-2017-0010","volume":"2","author":"E de Bree","year":"2017","unstructured":"de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum. 2017;2:47\u201362. https:\/\/doi.org\/10.1515\/pp-2017-0010.","journal-title":"Pleura Peritoneum."},{"issue":"6 Suppl 15","key":"10193_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/j.seminoncol.2004.11.021","volume":"31","author":"DR Budman","year":"2004","unstructured":"Budman DR. Dose and schedule as determinants of outcomes in chemotherapy for breast cancer. Semin Oncol. 2004;31(6 Suppl 15):3\u20139. https:\/\/doi.org\/10.1053\/j.seminoncol.2004.11.021.","journal-title":"Semin Oncol."},{"key":"10193_CR55","first-page":"693","volume":"53","author":"S Le Page","year":"2006","unstructured":"Le Page S, Kwiatkowski F, Paulin C, Mohamed F, Pezet D, Chipponi J, et al. In vitro thermochemotherapy of colon cancer cell lines with irinotecan alone and combined with mitomycin C. Hepatogastroenterology. 2006;53:693\u20137.","journal-title":"Hepatogastroenterology."},{"key":"10193_CR56","first-page":"214","volume":"24","author":"A Witkamp","year":"1998","unstructured":"Witkamp A. Dose finding study of hyperthermic intraperitoneal chemotherapy with mitomycin C in patients with carcinosis of colorectal origin. Eur J Surg Oncol. 1998;24:214.","journal-title":"Eur J Surg Oncol."},{"key":"10193_CR57","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00434396","volume":"5","author":"PB Johansen","year":"1981","unstructured":"Johansen PB. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother Pharmacol. 1981;5:267\u201370.","journal-title":"Cancer Chemother Pharmacol."},{"key":"10193_CR58","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00280-008-0800-0","volume":"63","author":"K Van der Speeten","year":"2009","unstructured":"Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother Pharmacol. 2009;63:799\u2013805. https:\/\/doi.org\/10.1007\/s00280-008-0800-0.","journal-title":"Cancer Chemother Pharmacol."},{"key":"10193_CR59","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1245\/s10434-011-1651-1","volume":"18","author":"E Cotte","year":"2011","unstructured":"Cotte E, Passot G, Tod M, Bakrin N, Gilly FN, Steghens A, et al. Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study. Ann Surg Oncol. 2011;18:2599\u2013603. https:\/\/doi.org\/10.1245\/s10434-011-1651-1.","journal-title":"Ann Surg Oncol."},{"key":"10193_CR60","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdf019","volume":"13","author":"D Elias","year":"2002","unstructured":"Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al. Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267\u201372.","journal-title":"Ann Oncol."},{"key":"10193_CR61","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1245\/s10434-008-9967-1","volume":"15","author":"JH Stewart","year":"2008","unstructured":"Stewart JH, Shen P, Russell GB, et al. A Phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancer. Ann Surg Oncol. 2008;15:2137\u201345.","journal-title":"Ann Surg Oncol."},{"key":"10193_CR62","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ijc.29011","volume":"136","author":"O Zivanovic","year":"2014","unstructured":"Zivanovic O, Abramian A, Kullmann M, Fuhrmann C, Coch C, Hoeller T, et al. HIPEC ROC I: a phase i study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer. 2014;136:699\u2013708.","journal-title":"Int J Cancer."},{"key":"10193_CR63","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ygyno.2016.05.032","volume":"142","author":"S Gouy","year":"2016","unstructured":"Gouy S, Ferron G, Glehen O, Bayar A, Marchal F, Pomel C, et al. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer. Gynecol Oncol. 2016;142:237\u201342. https:\/\/doi.org\/10.1016\/j.ygyno.2016.05.032.","journal-title":"Gynecol Oncol."},{"key":"10193_CR64","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00280-004-0779-0","volume":"54","author":"O Glehen","year":"2004","unstructured":"Glehen O, Stuart OA, Mohamed F, Sugarbaker PH. Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model. Cancer Chemother Pharmacol. 2004;54:79\u201384.","journal-title":"Cancer Chemother Pharmacol."},{"key":"10193_CR65","doi-asserted-by":"publisher","first-page":"827534","DOI":"10.1155\/2012\/827534","volume":"2012","author":"L Bijelic","year":"2012","unstructured":"Bijelic L, Sugarbaker PH, Stuart OA. Hyperthermic intraperitoneal chemotherapy with melphalan: a summary of clinical and pharmacological data in 34 patients.\u00a0Gastroenterol Res Pract. 2012;2012:827534. https:\/\/doi.org\/10.1155\/2012\/827534.","journal-title":"Gastroenterol Res Pract."},{"key":"10193_CR66","doi-asserted-by":"publisher","first-page":"161862","DOI":"10.1155\/2011\/161862","volume":"2011","author":"PH Sugarbaker","year":"2011","unstructured":"Sugarbaker PH, Stuart OA, Bijelic L. Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: rationale and report of early data. Int J Surg Oncol. 2011;2011:161862. https:\/\/doi.org\/10.1155\/2011\/161862.","journal-title":"Int J Surg Oncol."},{"key":"10193_CR67","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1158\/1078-0432.CCR-03-0486","volume":"10","author":"P Sabbatini","year":"2004","unstructured":"Sabbatini P, Aghajanian C, Leitao M, Venkatraman E, Anderson S, Dupont J, et al. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I\/II trial. Clin Cancer Res. 2004;10:2962\u20137.","journal-title":"Clin Cancer Res."},{"key":"10193_CR68","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1158\/1078-0432.CCR-06-1735","volume":"13","author":"RJ Morgan Jr","year":"2007","unstructured":"Morgan RJ Jr, Synold TW, Xi B, Lim D, Shibata S, Margolin K, et al. Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res. 2007;13:1232\u20137.","journal-title":"Clin Cancer Res."},{"key":"10193_CR69","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1245\/aso.2003.08.006","volume":"10","author":"F Mohamed","year":"2003","unstructured":"Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol. 2003;10:463\u20138. https:\/\/doi.org\/10.1245\/aso.2003.08.006.","journal-title":"Ann Surg Oncol."},{"key":"10193_CR70","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ctrv.2006.07.006","volume":"32","author":"E De Bree","year":"2006","unstructured":"De Bree E, Theodoropoulos PA, Rosing H, Michalakis J, Romanos J, Beijnen JH, et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat Rev. 2006;32:471\u201382.","journal-title":"Cancer Treat Rev."},{"key":"10193_CR71","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ejso.2006.03.008","volume":"32","author":"E De Bree","year":"2006","unstructured":"De Bree E, Rosing H, Michalakis J, Romanos J, Relakis K, Theodoropoulos PA, et al. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32:666\u201370.","journal-title":"Eur J Surg Oncol."},{"key":"10193_CR72","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s002800050870","volume":"43","author":"M Steller","year":"1999","unstructured":"Steller M, Egorin M, Trimble E, et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol. 1999;43:106\u201314. https:\/\/doi.org\/10.1007\/s002800050870.","journal-title":"Cancer Chemother Pharmacol."},{"key":"10193_CR73","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/00001813-200302000-00003","volume":"14","author":"E de Bree","year":"2003","unstructured":"de Bree E, Rosing H, Beijnen JH, Romanos J, Michalakis J, Georgoulias V, Tsiftsis DD. Pharmacokinetic study of docetaxel in intraoperative hyperthermic ip chemotherapy for ovarian cancer. Anticancer Drugs. 2003;14:103\u201310. https:\/\/doi.org\/10.1097\/00001813-200302000-00003.","journal-title":"Anticancer Drugs"},{"key":"10193_CR74","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00276-008-0456-9","volume":"31","author":"AM Albanese","year":"2009","unstructured":"Albanese AM, Albanese EF, Mino JH, et al. Peritoneal surface area: measurements of 40 structures covered by peritoneum: correlation between total peritoneal surface area and the surface calculated by formulas. Surg Radiol Anat. 2009;31:369\u201377.","journal-title":"Surg Radiol Anat."},{"key":"10193_CR75","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/oxfordjournals.ndt.a027189","volume":"11","author":"K Ates","year":"1996","unstructured":"Ates K, Erturk S, Nergisoglu G, et al. Sex-dependent variations in peritoneal membrane transport properties in CAPD patients. Nephrol Dialysis Transplant. 1996;11:2375\u20136.","journal-title":"Nephrol Dialysis Transplant."},{"key":"10193_CR76","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/jso.25437","volume":"119","author":"L Lemoine","year":"2019","unstructured":"Lemoine L, Thijssen E, Carleer R, Geboers K, Sugarbaker P, van der Speeten K. Body surface area-based vs concentration-based perioperative intraperitoneal chemotherapy after optimal cytoreductive surgery in colorectal peritoneal surface malignancy treatment: COBOX trial. J Surg Oncol. 2019;119:999\u20131010. https:\/\/doi.org\/10.1002\/jso.25437.","journal-title":"J Surg Oncol."},{"key":"10193_CR77","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1245\/s10434-013-3061-z","volume":"21","author":"K Turaga","year":"2014","unstructured":"Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, et al. Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014;21:1501\u20135.","journal-title":"Ann Surg Oncol."},{"key":"10193_CR78","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/PPO.0b013e3181a58d95","volume":"15","author":"K Van der Speeten","year":"2009","unstructured":"Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J. 2009;15:216\u201324. https:\/\/doi.org\/10.1097\/PPO.0b013e3181a58d95.","journal-title":"Cancer J."},{"key":"10193_CR79","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ejso.2018.10.542","volume":"45","author":"W Ceelen","year":"2019","unstructured":"Ceelen W. HIPEC with oxaliplatin for colorectal peritoneal metastasis: the end of the road? Eur J Surg Oncol. 2019;45:400\u20132. https:\/\/doi.org\/10.1016\/j.ejso.2018.10.542.","journal-title":"Eur J Surg Oncol."},{"key":"10193_CR80","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S1055-3207(03)00051-6","volume":"12","author":"DM Elias","year":"2003","unstructured":"Elias DM, Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin North Am. 2003;12:755\u201369.","journal-title":"Surg Oncol Clin North Am."},{"key":"10193_CR81","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(20)30322-3","volume":"21","author":"D Go\u00e9r\u00e9","year":"2020","unstructured":"Go\u00e9r\u00e9 D, Glehen O, Quenet F, Guilloit JM, Bereder JM, Lorimier G, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 2020;21:1147\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(20)30322-3.","journal-title":"Lancet Oncol."},{"key":"10193_CR82","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","volume":"4","author":"CEL Klaver","year":"2019","unstructured":"Klaver CEL, Wisselink DD, Punt CJA, Snaebjornsson P, Crezee J, Aalbers AGJ, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. COLOPEC Collaborators Group. Lancet Gastroenterol Hepatol. 2019;4:761\u201370. https:\/\/doi.org\/10.1016\/S2468-1253(19)30239-0.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10193_CR83","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12885-019-5545-0","volume":"19","author":"KP Rovers","year":"2019","unstructured":"Rovers KP, Bakkers C, Simkens GAAM, et al. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II\u2013III, randomised, superiority study (CAIRO6). BMC Cancer. 2019;19:390. https:\/\/doi.org\/10.1186\/s12885-019-5545-0.","journal-title":"BMC Cancer."},{"key":"10193_CR84","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00228-012-1405-4","volume":"69","author":"PH Cashin","year":"2013","unstructured":"Cashin PH, Ehrsson H, Wallin I, et al. Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis. Eur J Clin Pharmacol. 2013;69:533\u201340. https:\/\/doi.org\/10.1007\/s00228-012-1405-4.","journal-title":"Eur J Clin Pharmacol."},{"key":"10193_CR85","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1055-3207(03)00039-5","volume":"12","author":"F Mohamed","year":"2003","unstructured":"Mohamed F, Sugarbaker PH. Carrier solutions for intraperitoneal chemotherapy. Surg Oncol Clin N Am. 2003;12:813\u201324.","journal-title":"Surg Oncol Clin N Am."},{"key":"10193_CR86","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s002800000214","volume":"47","author":"SR Pestieau","year":"2001","unstructured":"Pestieau SR, Schnake KJ, Stuart OA, Sugarbaker PH. Impact of carrier solutions on the pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 2001;47:269\u201376.","journal-title":"Cancer Chemother Pharmacol."},{"key":"10193_CR87","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000012004","volume":"57","author":"S Tsujitani","year":"1999","unstructured":"Tsujitani S, Oka A, Kondo A, Katano K, Oka S, Saito H, et al. Administration in a hypotonic solution is preferable to dose escalation in intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in rats. Oncology. 1999;57:77\u201382.","journal-title":"Oncology."},{"key":"10193_CR88","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000066229","volume":"63","author":"D Elias","year":"2002","unstructured":"Elias D, El Otmany A, Bonnay M, Paci A, Ducreux M, Antoun S, et al. Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology. 2002;63:346\u201352.","journal-title":"Oncology."},{"key":"10193_CR89","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijpharm.2014.12.025","volume":"479","author":"AM Mehta","year":"2015","unstructured":"Mehta AM, Van den Hoven JM, Rosing H, Hillebrand MJ, Nuijen B, Huitema AD, Beijnen JH, Verwaal VJ. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharm. 2015;479:23\u20137. https:\/\/doi.org\/10.1016\/j.ijpharm.2014.12.025.","journal-title":"Int J Pharm."},{"key":"10193_CR90","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00280-005-0074-8","volume":"57","author":"PH Sugarbaker","year":"2006","unstructured":"Sugarbaker PH, Stuart OA, Carmignani CP. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol. 2006;57:703\u20138.","journal-title":"Cancer Chemother Pharmacol."},{"key":"10193_CR91","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","volume":"89","author":"RL Dedrick","year":"1997","unstructured":"Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst. 1997;89:480\u20137.","journal-title":"J Natl Cancer Inst."},{"key":"10193_CR92","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.sla.0000218089.61635.5f","volume":"244","author":"P Esquis","year":"2006","unstructured":"Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ysna MD, et al. High intraabdominal pressure enhances the penetration and antitumor effect of intra-peritoneal cisplatin on experimental carcinomatosis. Ann Surg. 2006;244:106\u201312.","journal-title":"Ann Surg."},{"key":"10193_CR93","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/00001813-199607000-00016","volume":"7","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Stuart OA, Chang D, Sugarbaker PH. Effect of intraabdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intra-peritoneal administration. Anti-Cancer Drugs. 1996;7:596\u2013603.","journal-title":"Anti-Cancer Drugs."},{"key":"10193_CR94","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1245\/s10434-007-9571-9","volume":"15","author":"A Gesson-Paute","year":"2008","unstructured":"Gesson-Paute A, Ferron G, Thomas F, de Lara EC, Chatelut E, Querleu D. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative chemotherapy (HIPEC): an experimental study. Ann Surg Oncol. 2008;15:339\u201344.","journal-title":"Ann Surg Oncol."},{"key":"10193_CR95","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejso.2019.06.022","volume":"47","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, Azmi N, Fumagalli L, Baratti D, Guaglio M, Cavalleri A, et al. Phase II randomized study on tissue distribution and pharmacokinetics of cisplatin according to different levels of intraabdominal pressure (IAP) during HIPEC (NCT02949791). Eur J Surg Oncol. 2021;47:82\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2019.06.022.","journal-title":"Eur J Surg Oncol."},{"key":"10193_CR96","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/026567399285765","volume":"15","author":"M Urano","year":"1999","unstructured":"Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperth. 1999;15:79\u2013107.","journal-title":"Int J Hyperth."},{"key":"10193_CR97","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/path.1700620303","volume":"62","author":"JS Young","year":"1950","unstructured":"Young JS, Lumsden CE, Stalker AL. The significance of the tissue pressure of normal testicular and of neoplastic (Brown-Pearce carcinoma) tissue in the rabbit. J Pathol Bacteriol. 1950;62:313\u201333.","journal-title":"J Pathol Bacteriol."},{"key":"10193_CR98","first-page":"487","volume":"52","author":"M Leunig","year":"1992","unstructured":"Leunig M, Goetz AE, Dellian M, Zetterer G, Gamarra F, Jain RK, Messmer K. Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res. 1992;52:487\u201390.","journal-title":"Cancer Res."},{"key":"10193_CR99","unstructured":"Hettinga VE. Reduction of Cisplatin Resistance by Hyperthermia. PhD Thesis, University of Groningen (ISBN 90-367-0648-3). Printpartners Ipskamp bv, Enschede, 1996."},{"key":"10193_CR100","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/bjc.1997.297","volume":"75","author":"VE Hetting","year":"1997","unstructured":"Hetting VE, Lemstra W, Meijer C, et al. Mechanism of hyperthermic potentiation of cisplatin action in cisplatin sensitive and -resistant tumor cells. Br J Cancer. 1997;75:1735\u201343.","journal-title":"Br J Cancer."},{"key":"10193_CR101","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/02656739709023545","volume":"13","author":"JV Hettinga","year":"1997","unstructured":"Hettinga JV, Konings AW, Kampinga HH. Reduction of cellular cisplatin resistance by hyperthermia: a review. Int J Hyperth. 1997;13:439\u201357.","journal-title":"Int J Hyperth."},{"key":"10193_CR102","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ejso.2006.03.004","volume":"32","author":"D Elias","year":"2006","unstructured":"Elias D, Raynard B, Bonnay M, Pocard M. Heated intraoperative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: pharmacologic studies. Eur J Surg Oncol. 2006;32:607\u201313.","journal-title":"Eur J Surg Oncol."},{"key":"10193_CR103","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/bjc.2014.602","volume":"112","author":"L Ansaloni","year":"2015","unstructured":"Ansaloni L, Coccolini F, Morosi L, et al. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. Br J Cancer. 2015;112:306\u201312. https:\/\/doi.org\/10.1038\/bjc.2014.602.","journal-title":"Br J Cancer."},{"key":"10193_CR104","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1245\/s10434-018-6631-2","volume":"25","author":"B Malgras","year":"2018","unstructured":"Malgras B, Gayat E, Aoun O, Lo Dico R, Eveno C, Pautrat K, et al. Impact of combination chemotherapy in peritoneal mesothelioma hyperthermic intraperitoneal chemotherapy (HIPEC): The RENAPE study: RENAPE Network. Ann Surg Oncol. 2018;25:3271\u20139. https:\/\/doi.org\/10.1245\/s10434-018-6631-2.","journal-title":"Ann Surg Oncol."},{"key":"10193_CR105","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/SLA.0b013e3182263933","volume":"254","author":"F Qu\u00e9net","year":"2011","unstructured":"Qu\u00e9net F, Go\u00e9r\u00e9 D, Mehta SS, Roca L, Dumont F, Hessissen M, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011;254:294\u2013301. https:\/\/doi.org\/10.1097\/SLA.0b013e3182263933.","journal-title":"Ann Surg."},{"key":"10193_CR106","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jso.2930540209","volume":"54","author":"Y Saikawa","year":"1993","unstructured":"Saikawa Y, Kubota T, Kuo TH, et al. Synergistic antitumor activity of mitomycin C and cisplatin against gastric cancer cells in vitro. J Surg Oncol. 1993;54:98\u2013102. https:\/\/doi.org\/10.1002\/jso.2930540209.","journal-title":"J Surg Oncol."},{"key":"10193_CR107","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/jso.2930560408","volume":"56","author":"Y Saikawa","year":"1994","unstructured":"Saikawa Y, Kubota T, Kuo TH, et al. Synergistic antitumor activity of combination chemotherapy with mitomycin C and cisplatin against human gastric cancer xenografts in nude mice. J Surg Oncol. 1994;56:242\u20135. https:\/\/doi.org\/10.1002\/jso.2930560408.","journal-title":"J Surg Oncol."},{"key":"10193_CR108","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1186\/1471-2407-14-807","volume":"14","author":"G Glockzin","year":"2014","unstructured":"Glockzin G, Gerken M, Lang SA, Klinkhammer-Schalke M, Piso P, Schlitt HJ. Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis. BMC Cancer. 2014;14:807.","journal-title":"BMC Cancer."},{"key":"10193_CR109","doi-asserted-by":"publisher","first-page":"20190025","DOI":"10.1515\/pp-2019-0025","volume":"4","author":"H Hakeam","year":"2019","unstructured":"Hakeam H, Ayman A, Waleed AT, Amen T. Systemic complications of the bidirectional intraoperative chemotherapy with intravenous ifosfamide and hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin plus doxorubicin. Pleura Peritoneum. 2019;4:20190025. https:\/\/doi.org\/10.1515\/pp-2019-0025.","journal-title":"Pleura Peritoneum."},{"key":"10193_CR110","volume-title":"Management of peritoneal metastases: cytoreductive surgery, HIPEC, and beyond","author":"K Van der Speeten","year":"2018","unstructured":"Van der Speeten K, Lemoine L. HIPEC Methodology, comparison of techniques, and drug regimens: is there a need for standardization? In: A Bhatt, editor. Management of peritoneal metastases: cytoreductive surgery, HIPEC, and beyond. Singapore: Springer; 2018."},{"key":"10193_CR111","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Peritoneal\u2013plasma barrier. Cancer Treat Res. 1996;82:53\u201363.","journal-title":"Cancer Treat Res."},{"key":"10193_CR112","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00280-003-0626-8","volume":"52","author":"Vazquez V De Lima","year":"2003","unstructured":"De Lima Vazquez V, Stuart OA, Mohamed F, Sugarbaker PH. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother Pharmacol. 2003;52:108\u201312.","journal-title":"Cancer Chemother Pharmacol."},{"key":"10193_CR113","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000011847","volume":"55","author":"P Jacquet","year":"1998","unstructured":"Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology. 1998;55:130\u20138.","journal-title":"Oncology."},{"key":"10193_CR114","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ejso.2011.04.007","volume":"37","author":"PH Sugarbaker","year":"2011","unstructured":"Sugarbaker PH, Van Der Speeten K, Anthony Stuart O, Chang D. Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis. Eur J Surg Oncol. 2011;37:719\u201326.","journal-title":"Eur J Surg Oncol."},{"key":"10193_CR115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2486\/indhealth.2014-0025","volume":"53","author":"AF Villa","year":"2015","unstructured":"Villa AF, El Balkhi S, Aboura R, Sageot H, Hasni-Pichard H, Pocard M, et al. Evaluation of oxaliplatin exposure of healthcare workers during heated intraperitoneal perioperative chemotherapy (HIPEC). Ind Health. 2015;53:28\u201337.","journal-title":"Ind Health."},{"key":"10193_CR116","first-page":"431","volume":"1","author":"D Elias","year":"2000","unstructured":"Elias D, Antoun S, Goharin A, Otmany AE, Puizillout JM, Lasser P. Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Investig. 2000;1:431\u20139.","journal-title":"Int J Surg Investig."},{"key":"10193_CR117","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4251\/wjgo.v12.i7.756","volume":"12","author":"JL Leiting","year":"2020","unstructured":"Leiting JL, Cloyd JM, Ahmed A, Fournier K, Lee AJ, Dessureault S, et al. Comparison of open and closed hyperthermic intraperitoneal chemotherapy: results from the United States hyperthermic intraperitoneal chemotherapy collaborative. World J Gastrointest Oncol. 2020;12:756\u201367.","journal-title":"World J Gastrointest Oncol."},{"key":"10193_CR118","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/bjs.11206","volume":"106","author":"I Ubink","year":"2019","unstructured":"Ubink I, Bolhaqueiro ACF, Elias SG, Raats DAE, Constantinides A, Peters NA, et al. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy. Br J Surg. 2019;106:1404\u201314. https:\/\/doi.org\/10.1002\/bjs.11206.","journal-title":"Br J Surg."},{"key":"10193_CR119","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1245\/s10434-018-7008-2","volume":"26","author":"KI Votanopoulos","year":"2019","unstructured":"Votanopoulos KI, Mazzocchi A, Sivakumar H, et al. Appendiceal cancer patient-specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment: a feasibility study. Ann Surg Oncol. 2019;26:139\u201347. https:\/\/doi.org\/10.1245\/s10434-018-7008-2.","journal-title":"Ann Surg Oncol."},{"key":"10193_CR120","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.1245\/s10434-020-08790-2","volume":"27","author":"SD Forsythe","year":"2020","unstructured":"Forsythe SD, Sasikumar S, Moaven O, et al. Personalized identification of optimal HIPEC perfusion protocol in patient-derived tumor organoid platform. Ann Surg Oncol. 2020;27:4950\u201360. https:\/\/doi.org\/10.1245\/s10434-020-08790-2.","journal-title":"Ann Surg Oncol."},{"key":"10193_CR121","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3390\/jcm7120567","volume":"7","author":"C Yurttas","year":"2018","unstructured":"Yurttas C, Hoffmann G, Tolios A, Haen SP, Schwab M, K\u00f6nigsrainer I, et al. Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer. J Clin Med. 2018;7:567. https:\/\/doi.org\/10.3390\/jcm7120567.","journal-title":"J Clin Med."},{"key":"10193_CR122","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1245\/s10434-019-07935-2","volume":"27","author":"D Baratti","year":"2020","unstructured":"Baratti D, Kusamura S, Azmi N, Guaglio M, Montenovo M, Deraco M. Colorectal peritoneal metastases treated by perioperative systemic chemotherapy and cytoreductive surgery with or without mitomycin C-based HIPEC: a comparative study using the Peritoneal Surface Disease Severity Score (PSDSS). Ann Surg Oncol. 2020;27:98\u2013106. https:\/\/doi.org\/10.1245\/s10434-019-07935-2.","journal-title":"Ann Surg Oncol."},{"key":"10193_CR123","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejso.2016.09.015","volume":"43","author":"V Leung","year":"2017","unstructured":"Leung V, Huo YR, Liauw W, Morris DL. Oxaliplatin versus mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43:144\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2016.09.015.","journal-title":"Eur J Surg Oncol."},{"key":"10193_CR124","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/jso.23728","volume":"110","author":"A Prada-Villaverde","year":"2014","unstructured":"Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. Surg Oncol. 2014;110:779\u201385. https:\/\/doi.org\/10.1002\/jso.23728.","journal-title":"Surg Oncol."},{"key":"10193_CR125","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jamcollsurg.2017.12.02","volume":"226","author":"EA Levine","year":"2018","unstructured":"Levine EA, Votanopoulos KI, Shen P, et al. A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors (published correction appears in J Am Coll Surg. 2018;227:633). J Am Coll Surg. 2018;226:434\u201343. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2017.12.02.","journal-title":"J Am Coll Surg."},{"key":"10193_CR126","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00280-014-2525-6","volume":"74","author":"Q Chalret du Rieu","year":"2014","unstructured":"Chalret du Rieu Q, White-Koning M, Picaud L, Lochon I, Marsili S, Gladieff L, et al. Population pharmacokinetics of peritoneal, plasma ultrafiltrated, and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia. Cancer Chemother Pharmacol. 2014;74:571\u201382.","journal-title":"Cancer Chemother Pharmacol."},{"key":"10193_CR127","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1245\/s10434-016-5143-1","volume":"23","author":"T Charrier","year":"2016","unstructured":"Charrier T, Passot G, Peron J, Maurice C, Gocevska S, Quenet F, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors. Ann Surg Oncol. 2016;23:2315\u201322.","journal-title":"Ann Surg Oncol."},{"key":"10193_CR128","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jso.23546","volume":"109","author":"D Hompes","year":"2014","unstructured":"Hompes D, D\u2019Hoore A, Wolthuis A, Fieuws S, Mirck B, Bruin S, Verwaal V. The use of oxaliplatin or mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol. 2014;109:527\u201332. https:\/\/doi.org\/10.1002\/jso.23546.","journal-title":"J Surg Oncol."},{"key":"10193_CR129","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/j.jss.2012.01.015","volume":"179","author":"K Votanopoulos","year":"2013","unstructured":"Votanopoulos K, Ihemelandu C, Shen P, Stewart J, Russell G, Levine EA. A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res. 2013;179:e133\u20139. https:\/\/doi.org\/10.1016\/j.jss.2012.01.015.","journal-title":"J Surg Res."},{"key":"10193_CR130","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejso.2017.10.216","volume":"44","author":"WJ van Eden","year":"2018","unstructured":"van Eden WJ, Kok NFM, Woensdregt K, Huitema ADR, Boot H, Aalbers AGJ. Safety of intraperitoneal mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2018;44:220\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2017.10.216.","journal-title":"Eur J Surg Oncol."},{"key":"10193_CR131","doi-asserted-by":"publisher","first-page":"1920276","DOI":"10.1155\/2018\/1920276","volume":"2018","author":"A Sipok","year":"2018","unstructured":"Sipok A, Sardi A, Nieroda C, King MC, Sittig M, Gushchin V. Comparison of survival in patients with isolated peritoneal carcinomatosis from colorectal cancer treated with cytoreduction and melphalan or mitomycin C as hyperthermic intraperitoneal chemotherapy agent. Int J Surg Oncol, 2018;2018:1920276.\u00a0https:\/\/doi.org\/10.1155\/2018\/1920276.","journal-title":"Int J Surg Oncol."},{"issue":"10 Pt A","key":"10193_CR132","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.ejso.2020.04.018","volume":"46","author":"C Bakkers","year":"2020","unstructured":"Bakkers C, van Erning FN, Rovers KP, Nienhuijs SW, Burger JW, Lemmens VE, et al. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: a nationwide comparative study. Eur J Surg Oncol. 2020;46(10 Pt A):1902\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2020.04.018.","journal-title":"Eur J Surg Oncol."},{"key":"10193_CR133","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ygyno.2007.03.019","volume":"106","author":"JH Bae","year":"2007","unstructured":"Bae JH, Lee JM, Ryu KS, et al. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol. 2007;106:193\u2013200.","journal-title":"Gynecol Oncol."},{"key":"10193_CR134","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.suronc.2016.05.010","volume":"25","author":"P Cascales-Campos","year":"2016","unstructured":"Cascales-Campos P, L\u00f3pez-L\u00f3pez V, Gil J, Ar\u00e9valo-P\u00e9rez J, Nieto A, Barcel\u00f3 F, et al. Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C\/IV ovarian cancer: is there any difference? Surg Oncol. 2016;25:164\u201370. https:\/\/doi.org\/10.1016\/j.suronc.2016.05.010.","journal-title":"Surg Oncol."},{"key":"10193_CR135","first-page":"305","volume":"20","author":"H Gurney","year":"2001","unstructured":"Gurney H, Ackland S, Liddle C, Dunleavey R, Rivory L, Farlow D, et al. Determining the drug elimination phenotype: hepatic sestamibi scan and midazolam clearance as in vivo tests for drug metabolism and biliary elimination (abstract). Proc Am Soc Clin Oncol. 2001;20:305.","journal-title":"Proc Am Soc Clin Oncol."},{"key":"10193_CR136","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.1998.16.7.2299","volume":"16","author":"HP Gurney","year":"1998","unstructured":"Gurney HP, Ackland S, Gebski V, Farrell G. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol. 1998;16:2299\u20133004.","journal-title":"J Clin Oncol."},{"key":"10193_CR137","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1200\/JCO.1998.16.7.2297","volume":"16","author":"MJ Ratain","year":"1998","unstructured":"Ratain MJ. Body surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol. 1998;16:2297\u20138.","journal-title":"J Clin Oncol."},{"key":"10193_CR138","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1200\/JCO.1996.14.9.2590","volume":"14","author":"H Gurney","year":"1996","unstructured":"Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996;14:2590\u2013611.","journal-title":"J Clin Oncol."},{"key":"10193_CR139","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1200\/JCO.1997.15.5.1844","volume":"15","author":"A Horwich","year":"1997","unstructured":"Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic non-seminomatous germ cell cancer: a Multi-institutional Medical Research Council\/European Organization for Research and Treatment of Cancer trial. J Clin Oncol. 1997;15:1844\u201352.","journal-title":"J Clin Oncol."},{"key":"10193_CR140","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/sj.bjc.6600139","volume":"86","author":"H Gurney","year":"2002","unstructured":"Gurney H. How to calculate the dose of chemotherapy. Br J Cancer. 2002;86:1297\u2013302. https:\/\/doi.org\/10.1038\/sj.bjc.6600139.","journal-title":"Br J Cancer."},{"key":"10193_CR141","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12885-018-4365-y","volume":"18","author":"S Liutkauskiene","year":"2018","unstructured":"Liutkauskiene S, Grizas S, Jureniene K, et al. Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes. BMC Cancer. 2018;18:453. https:\/\/doi.org\/10.1186\/s12885-018-4365-y.","journal-title":"BMC Cancer."},{"key":"10193_CR142","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12885-018-4380-z","volume":"18","author":"S Munker","year":"2018","unstructured":"Munker S, Gerken M, Fest P, et al. Chemotherapy for metastatic colon cancer: no effect on survival when the dose is reduced due to side effects. BMC Cancer. 2018;18:455. https:\/\/doi.org\/10.1186\/s12885-018-4380-z.","journal-title":"BMC Cancer."},{"key":"10193_CR143","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490. https:\/\/doi.org\/10.1136\/bmj.328.7454.1490.","journal-title":"BMJ."},{"key":"10193_CR144","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction: GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383\u201394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026.","journal-title":"J Clin Epidemiol."},{"key":"10193_CR145","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jso.21061","volume":"98","author":"O Glehen","year":"2008","unstructured":"Glehen O, Cotte E, Kusamura S, Deraco M, Baratti D, Passot G, et al. Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol. 2008;98:242\u20136.","journal-title":"J Surg Oncol."},{"key":"10193_CR146","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1245\/ASO.2003.01.018","volume":"10","author":"O Glehen","year":"2003","unstructured":"Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863\u20139.","journal-title":"Ann Surg Oncol."},{"key":"10193_CR147","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/bjs.1800780119","volume":"78","author":"T Shimizu","year":"1991","unstructured":"Shimizu T, Maeta M, Koga S. Influence of local hyperthermia on the healing of small intestinal anastomoses in the rat. Br J Surg. 1991;78:57\u20139.","journal-title":"Br J Surg."},{"key":"10193_CR148","first-page":"39","volume":"169","author":"E De Bree","year":"2007","unstructured":"De Bree E, Tsiftsis DD. Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. Recent Results Cancer Res. 2007;169:39\u201351.","journal-title":"Recent Results Cancer Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10193-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-10193-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10193-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T21:31:47Z","timestamp":1699133507000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-10193-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":148,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10193"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-10193-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]},"assertion":[{"value":"19 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}